Pipeline With our clinical and preclinical research programs we evaluate imlifidase and HNSA-5487 across a spectrum of both potential disease areas and indications.

Feb 6, 2025 · The call will include a review of the interim results and a business and pipeline update. It will be held in English. Slides used in the presentation will be live on the company …

2 days ago · Stay informed on Hansa Biopharma's latest news, financial and annual reports, upcoming investor events and more.

Nov 5, 2025 · We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on …

Jul 17, 2025 · The call will include a review of the interim results and a business and pipeline update. It will be held in English. Slides used in the presentation will be live on the company …

Oct 30, 2025 · Pipeline Progress U.S. ConfIdeS trial: Imlifidase successfully achieved its primary endpoint in the U.S. Phase 3 pivotal ConfIdeS study in kidney transplantation.

In addition, there are three key challenges many biotech companies face as they mature and advance pipeline projects towards regulatory approval and market launch – 1) transitioning …

Mar 21, 2025 · With year-on-year IDEFIRIX® sales growth of 83%, a successful financing round, and several critical pipeline catalysts for imlifidase and HNSA-5487, 2024 has positioned us …

Oct 11, 2023 · Clinical pipeline update Hansa has made good progress on patient enrollment in two key trials in autoimmune diseases. • GOOD-IDES-02: Nine of 50 targeted patients …